Anti-SMARCA2 antibody produced in rabbit

Description

• General description: SMARCA2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 2) gene is mapped in human chromosome 9p24.3. SMARCA2 is also known as BRM(Brahma) and is an important catalytic component of the SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex.
• Immunogen: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: The components of SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex is often regarded as tumor suppressors. SMARCA2 along with SMARCA4 is an ATPase of the complex. SMARCA2 might be post-translationally silenced in many cancers. The loss of this gene expression might be as a result of epigenetic or post-translational modifications and may not be due to gene mutation in pancreatic and lung cancer cell lines. The expression of SMARCA2 is regulated by histone deacetylases HDAC3 (Histone deacetylases) and HDAC9 (Histone deacetylases), along with transcription factors MEF2D (myocyte enhancer factor 2D) and GATA3 (GATA binding protein 3). Loss of both SMARCA2 and SMARCA4 is specifically observed in small cell carcinoma of the ovary hypercalcaemic type.. The expression of SMARCA2 is retained by histone deacetylase inhibitor trichostatin A. Nicolaides-Baraitser syndrome involves SMARCA2 mutation.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST86802
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.